# SR One Capital Management, LP: Form 13F holdings

An institutional investment manager in Redwood City, CA. SEC CIK 1910264.

- Quarter ended: 2026-06-30
- Filed: 2026-08-12
- Reported value: $1.04bn
- Positions: 15 (15 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1910264/000119312526347065/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [Veradermics, Inc. (MANE)](/companies/mane.md) | Common Stock | $295.3m | 28.4% | 2,401,868 |  | Unchanged |
| [Zenas BioPharma, Inc (ZBIO)](/companies/zbio.md) | Common Stock | $127.9m | 12.3% | 5,037,854 |  | Unchanged |
| CRISPR Therapeutics AG | Common Shares | $111.2m | 10.7% | 2,038,763 |  | Unchanged |
| [Avalyn Pharma, Inc (AVLN)](/companies/avln.md) | Common Stock | $108.9m | 10.5% | 3,308,649 |  | New +3,308,649 |
| [Design Therapeutics, Inc. (DSGN)](/companies/dsgn.md) | Common Stock | $94.4m | 9.1% | 6,526,476 |  | Unchanged |
| [Odyssey Therapeutics, Inc. (ODTX)](/companies/odtx.md) | Common Stock | $71.0m | 6.8% | 3,794,883 |  | New +3,794,883 |
| [Alumis Inc. (ALMS)](/companies/alms.md) | Common Stock | $55.2m | 5.3% | 1,959,896 |  | Unchanged |
| [ORIC Pharmaceuticals, Inc. (ORIC)](/companies/oric.md) | Common Stock | $50.0m | 4.8% | 4,615,384 |  | Added +100,455 |
| [Mineralys Therapeutics Inc. (MLYS)](/companies/mlys.md) | Common Stock | $42.2m | 4.1% | 1,563,966 |  | Unchanged |
| [ARS Pharmaceuticals, Inc. (SPRY)](/companies/spry.md) | Common Stock | $32.1m | 3.1% | 4,012,903 |  | Unchanged |
| [Mobia Medical, Inc (MOBI)](/companies/mobi.md) | Common Stock | $26.6m | 2.6% | 1,986,072 |  | New +1,986,072 |
| [Nkarta, Inc. (NKTX)](/companies/nktx.md) | Common Stock | $9.4m | 0.9% | 3,333,333 |  | Unchanged |
| Oculis Holding AG | Ordinary Shares | $8.9m | 0.9% | 641,022 |  | Unchanged |
| [Ultragenyx Pharmaceutical Inc. (RARE)](/companies/rare.md) | Common Stock | $4.6m | 0.4% | 137,753 |  | Unchanged |
| enGene Holdings Inc. | Common Shares | $1.3m | 0.1% | 747,750 |  | Unchanged |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| Arcellx, Inc. | Common Stock | $0 | 0.0% | 0 |  | Sold out −2,346,630 |
| [Oruka Therapeutics, Inc (ORKA)](/companies/orka.md) | Common Stock | $0 | 0.0% | 0 |  | Sold out −430,330 |

Source: SEC EDGAR, Form 13F-HR, accession 0001193125-26-347065. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.